PYXS vs. SLRN, CRDF, URGN, AVIR, IMMP, ENGN, DMAC, FHTX, DRUG, and TSVT
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Acelyrin (SLRN), Cardiff Oncology (CRDF), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Immutep (IMMP), enGene (ENGN), DiaMedica Therapeutics (DMAC), Foghorn Therapeutics (FHTX), Bright Minds Biosciences (DRUG), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs.
Pyxis Oncology (NASDAQ:PYXS) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
Pyxis Oncology currently has a consensus target price of $9.20, indicating a potential upside of 776.19%. Acelyrin has a consensus target price of $9.60, indicating a potential upside of 277.95%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Acelyrin.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 9.8% of Pyxis Oncology shares are held by insiders. Comparatively, 13.6% of Acelyrin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Pyxis Oncology's return on equity of -36.22% beat Acelyrin's return on equity.
Pyxis Oncology received 14 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 83.33% of users gave Pyxis Oncology an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
Pyxis Oncology has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
In the previous week, Pyxis Oncology had 18 more articles in the media than Acelyrin. MarketBeat recorded 23 mentions for Pyxis Oncology and 5 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.01 beat Pyxis Oncology's score of 0.87 indicating that Acelyrin is being referred to more favorably in the news media.
Pyxis Oncology has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Pyxis Oncology beats Acelyrin on 12 of the 16 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy PYXS Stock Free PYXS Stock Alerts